Bicocca Open Archive

Logo unimib boa
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 29.101
NA - Nord America 6.904
EU - Europa 5.846
SA - Sud America 4.781
AF - Africa 610
OC - Oceania 234
Continente sconosciuto - Info sul continente non disponibili 8
Totale 47.484
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 12.582
SG - Singapore 6.052
US - Stati Uniti d'America 5.816
CN - Cina 4.531
BR - Brasile 3.392
HK - Hong Kong 1.834
IT - Italia 1.138
RU - Federazione Russa 833
KR - Corea 683
FR - Francia 676
TR - Turchia 675
MX - Messico 669
DE - Germania 556
IN - India 542
ES - Italia 537
AR - Argentina 452
GB - Regno Unito 355
ID - Indonesia 351
JP - Giappone 325
FI - Finlandia 313
BD - Bangladesh 286
CA - Canada 285
CO - Colombia 275
AU - Australia 214
EC - Ecuador 183
IQ - Iraq 180
PK - Pakistan 173
NL - Olanda 169
SA - Arabia Saudita 165
PL - Polonia 152
AT - Austria 151
CL - Cile 151
ZA - Sudafrica 144
VE - Venezuela 113
EG - Egitto 107
PH - Filippine 105
SE - Svezia 98
GR - Grecia 96
PT - Portogallo 92
MA - Marocco 88
UA - Ucraina 87
CZ - Repubblica Ceca 83
PE - Perù 81
CH - Svizzera 80
PY - Paraguay 71
UZ - Uzbekistan 69
KZ - Kazakistan 68
TN - Tunisia 60
DZ - Algeria 59
IL - Israele 59
TW - Taiwan 54
NO - Norvegia 53
MY - Malesia 49
RO - Romania 44
HU - Ungheria 43
KE - Kenya 43
AE - Emirati Arabi Uniti 40
MD - Moldavia 36
TH - Thailandia 36
BE - Belgio 35
HR - Croazia 32
BO - Bolivia 31
NP - Nepal 31
JO - Giordania 29
UY - Uruguay 29
SK - Slovacchia (Repubblica Slovacca) 28
AZ - Azerbaigian 27
CR - Costa Rica 27
DO - Repubblica Dominicana 27
IE - Irlanda 26
OM - Oman 24
ET - Etiopia 23
DK - Danimarca 22
GT - Guatemala 20
NZ - Nuova Zelanda 20
SI - Slovenia 19
AL - Albania 18
LT - Lituania 17
RS - Serbia 17
SN - Senegal 17
LB - Libano 15
PS - Palestinian Territory 15
SY - Repubblica araba siriana 13
JM - Giamaica 11
GE - Georgia 10
HN - Honduras 10
NG - Nigeria 10
BY - Bielorussia 9
KG - Kirghizistan 9
LK - Sri Lanka 9
LY - Libia 9
PA - Panama 9
QA - Qatar 9
AO - Angola 8
BG - Bulgaria 8
XK - ???statistics.table.value.countryCode.XK??? 8
BH - Bahrain 7
EE - Estonia 7
IR - Iran 7
KW - Kuwait 7
Totale 47.363
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 4.014
Hanoi 3.211
Singapore 2.612
Hong Kong 1.770
Hefei 1.647
San Jose 1.147
Seoul 637
Chicago 523
Ashburn 490
Lauterbourg 397
Da Nang 350
Haiphong 343
São Paulo 332
Los Angeles 326
Ha Long 291
The Dalles 288
Dallas 254
Quận Bình Thạnh 247
Biên Hòa 246
Buffalo 245
Helsinki 237
Istanbul 213
Hải Dương 210
Milan 200
Ninh Bình 198
Beijing 195
Thái Nguyên 191
Vũng Tàu 177
New York 176
Can Tho 173
Melbourne 173
Moscow 166
Bắc Ninh 145
Rome 145
Rio de Janeiro 143
Ankara 135
Jakarta 123
Madrid 120
Bắc Giang 118
Frankfurt am Main 114
Council Bluffs 113
Quận Một 113
Phủ Lý 107
Quận Phú Nhuận 106
Tokyo 98
Shanghai 97
Guangzhou 94
Mexico City 94
Bogotá 90
Montreal 89
Quận Sáu 88
Thái Bình 79
Vinh 77
Santiago 76
Baghdad 74
Brasília 72
Lấp Vò 72
Barcelona 71
Buenos Aires 71
Curitiba 71
Quito 70
Quận Tân Phú 69
Vienna 69
Lang Son 68
Uyen Hung 68
Medellín 67
Điện Bàn 65
Belo Horizonte 64
Jeddah 64
Paris 63
Riyadh 63
London 62
Lima 60
Vĩnh Tường 59
Dhaka 58
Guadalajara 58
Hangzhou 58
Karachi 58
Nuremberg 58
Quận Năm 58
Tashkent 58
Quảng Ninh 55
Thu Dau Mot 55
Amsterdam 52
Santa Clara 52
Cairo 51
Bến Tre 50
Manchester 50
Quận Bảy 50
Porto Alegre 49
Thành Phố Bà Rịa 49
Cologne 48
Johannesburg 48
Goiânia 47
Lappeenranta 47
Bình Dương 46
Fortaleza 46
Huế 46
Lahore 46
Salvador 46
Totale 26.724
Salva come PNG Salva come JPEG
Nome #
Juvenile idiopathic arthritis 3.753
Classification criteria for autoinflammatory recurrent fevers 2.099
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial 1.271
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial 906
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 592
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist 539
Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus 482
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept 419
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 409
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 406
Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study 402
Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides 397
Macrophage Activation Syndrome in Juvenile Systemic Lupus Erythematosus A Multinational Multicenter Study of Thirty-Eight Patients 378
Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? 378
The Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 372
The Korean version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 369
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 368
The Bulgarian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 360
The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 358
Is It Time to Move to Active Comparator Trials in Juvenile Idiopathic Arthritis? A Review of Current Study Designs 353
EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation 339
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial 331
Localized scleroderma in childhood is not just a skin disease 328
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis 323
Criteria to define response to therapy in paediatric rheumatic diseases 319
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results 264
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 253
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist 241
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 239
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 239
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 235
Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) (Rheumatology International, (2018), 38, S1, (251-258), 10.1007/s00296-018-3960-1) 234
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 227
Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases 221
Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 216
Is minimal clinically important difference relevant for the interpretation of clinical trials in pediatric rheumatic diseases? 213
The Russian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 210
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 207
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis 205
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 205
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis 203
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis 202
The Argentinian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 200
Do the Provisional Paediatric Rheumatology International Trials Organisation Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis Criteria Capture Youth With Axial Spondyloarthritis? 200
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicenter PRINTO study 197
Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis 196
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial 194
An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis 188
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study 180
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 176
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases 175
Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus 175
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 169
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 167
Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study 167
Measures of Adult and Juvenile Dermatomyositis, Polymyositis, and Inclusion Body Myositis Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) 166
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 164
Effect of Characteristic Inflammatory and Structural Pelvic Magnetic Resonance Imaging Lesions on Expert Assessment of Axial Juvenile Spondyloarthritis 164
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 161
Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind 158
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis 157
Adalimumab in Juvenile Rheumatoid Arthritis Reply 157
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis 154
Monitoring of Adverse Events and Safety in Autoinflammatory Diseases: Real-Life Data from the Eurofever Registry 153
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis 150
The Paediatric Rheumatology International Trials Organisation Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis 150
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 150
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 149
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 147
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis 144
A randomized trial of parenteral methotrexate comparing an intermediate with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate 142
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 141
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project 139
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry 135
Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey 131
Thrombotic manifestations in pediatric Behcet syndrome: A multicenter comparative study from the EUROFEVER registry 129
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis 129
Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis 129
The Provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study 129
Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study 128
Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis 128
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 126
Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate 126
Transcriptional Profiling of Tofacitinib Treatment in Juvenile Idiopathic Arthritis: Implications for Treatment Response Prediction 124
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 123
Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study 122
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 122
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 121
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis 121
Summary of Research: Ten-Year Safety and Clinical Benefit from Open-Label Etanercept Treatment in Children and Young Adults with Juvenile Idiopathic Arthritis 121
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 119
Porpora di Schönlein-Henoch in paziente con pregressa glomerulonefrite di Berger (Schönlein-Henoch purpura in patients with previous Berger's glomerulonephritis) 119
TNFRSF1A-pR92Q variant identifies a subset of patients more similar to systemic undifferentiated recurrent fever than TNF receptor-associated periodic syndrome 118
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study 118
Correction: A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry [Pediatr Rheumatol., 15, (2017) (84)] DOI: 10.1186/s12969-017-0213-x 115
Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles 114
Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries 114
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis 114
JIA, Today and Tomorrow 113
The Finnish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) 111
Totale 28.494
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.757
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.757
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202510.043 0 0 0 0 605 129 1.200 822 1.717 1.474 1.228 2.868
2025/202639.121 10.069 7.688 3.113 4.583 1.858 1.286 3.311 1.998 2.212 2.449 554 0
Totale 49.164